SUMMARYDuring fiscal year 2022, the NCI awarded a total of 1,358 competing Research Project Grants (RPGs; see Table 2), which represented an overall success rate  of 15% for all RPG applications and 14% for unsolicited  R01/R37 applications. For unsolicited R01/R37 grant applications in 2022, the number of R01/R37 awards was similar to 2021 (805 vs. 811). The total number of applications were fewer in 2022 (8,932 vs 9,701), which accounted for the overall success rate being higher than in 2021 (15% vs. 14%). Unsolicited R01/R37 and R21 grants represented 75% of the total number of awards for 2022. NCI funded all unsolicited R01/R37 applications with scores up to and including the 11th percentile  and unsolicited R21 applications with scores up to and including the 9th percentile. In addition, R03 and R15 applications with impact scores  up to and including a score of 25 were funded.
Special consideration continued to be given to R01 applications from Early Stage Investigators ; as a result, all applications in this group with scores up to and including the 16th percentile were funded. An additional 12 meritorious ESI applications were selected for funding beyond the 16th percentile . Beginning in fiscal year 2017 NCI further elevated priorities for supporting the next generation of talented cancer researchers by converting R01 ESI applications that fell within the Experienced Investigator (EI) payline for that year (the 11th percentile for 2022) into MERIT R37 awards for an additional 2 years of support beyond the initial award period .
NCI also funded some applications with scores beyond the payline after review and approval by NCI's Divisions and Scientific Program Leaders during special meetings with the NCI Director. The graphs that appear below summarize the overall funding patterns for R01/R37s and R21s across various categories of investigators.
The R35 Outstanding Investigator Award (OIA) supports investigators with outstanding records of productivity in cancer research by providing extended funding stability to pursue their innovative studies. OIA recipients are required to commit at least 50% effort to the OIA research. NCI will only consider funding two additional grants to the Outstanding Investigator while the OIA is active. This limit includes single PD/PI, multiple PD/PI, and multi-project grants.
The R50 Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to pursue research within the context of an existing cancer research program, but not serve as independent investigators. These scientists, such as researchers within a research program, core facility managers, and data scientists, are vital to sustaining the biomedical research enterprise.
Beginning in fiscal year 2017, the NCI supported The Cancer MoonshotSM to accelerate scientific discovery in cancer, foster greater collaboration, and improve the sharing of data. The figures and displays represented include funding supported by the Cancer MoonshotSM.
- - FY 2022 R01/R37
- - FY 2022 R21
- - Table 1: Fiscal Year 2022: Success Rates (unsolicited R01s, R37s and R21s)
- - Table 2: All Competing Research Project Grants
- - Comments
Funding Patterns for R01/R37 Applications
The graph in Figure 1 summarizes the number of percentiled R01/R37 applications received and grants funded at each percentile, among all investigators. As expected, beyond the 11th percentile, the number of grants funded decreased in proportion to the percentile ranking. Nevertheless, 17% of these awards had rankings beyond the 11th percentile.
Similar displays are shown below for experienced investigators (applicants who have received a prior R01/R37 award and were applying for a new grant or a competitive renewal; Figure 2); new investigators , which includes early stage investigators  (Figure 3); and early stage investigators  (Figure 4). Similar patterns are observed in all cases. Success rates have not been plotted for new and early stage investigators because of the small numbers of applications at each percentile score. For Success Rate comparisons, refer to Tables 1 and 2 below.
Funding Patterns in previous years are posted at: Articles.
 The success rate is the percentage of applications received that are funded. It is calculated by dividing the number of funded grants by the number of applications received. When an amended application is considered in the same fiscal year as the original, only the application with the better score is counted in the number of applications received.
 A percentile is a score that ranks competing applications against others in the same study section in the past year. It is intended to allow a comparison of impact scores  of applications across all study sections.
 A New Investigator is one who has not previously competed successfully for an R01 or other substantial NIH independent research award. New Investigators who are not Early Stage Investigators are not eligible for the extended payline. An Early Stage Investigator is a New Investigator who is within 10 years of completing his/her terminal research degree or medical residency (or the equivalent). A more detailed definition can be found at: https://grants.nih.gov/policy/new_investigators/index.htm#definition.
 The impact score is given by each individual scientific reviewer's assessment of the scored criteria plus additional criteria regarding the protection and inclusion of human subjects; vertebrate animal care and welfare; biohazards, and criteria specific to the funding opportunity and is based on the overall impact that the project is likely to have on the research field(s) involved.
 An unsolicited application is an investigator initiated application and is not an application in response to an RFA.
 R01 ESIs converting to MERIT R37 awards are dependent on recommendations from the National Cancer Advisory Board (NCAB).
NCI FY2022: "Percentiled" R01/R37 Applications, Awards, and Success Rates
Figure 1: All Investigators: Experienced, New and Early Stage
Figure 1:In some cases, applications scoring within the payline were determined ineligible for funding due to overlap.
NCI FY2022 Competing R01/R37 Applications and Awards
Figure 3: New Investigators (Includes Early Stage Investigators)
Figures 1-4: Excludes applications that did not receive a percentile ranking. When an amended application is considered in the same fiscal year as the original, only the one with the better ranking is counted.
Funding Patterns for R21 Applications
The funding patterns for R21 grant applications differ from those of R01/R37 applications. The patterns are explained by the fact that NCI receives a disproportionate number of applications relative to the number of R21 grants that can be funded (refer to Table 1). Of the competing R21s funded, 6% had rankings beyond the 9th percentile. NCI has seen a decrease in unsolicited R21 applications from last year by 167 (1,603 vs. 1,770).
In contrast to R01/R37 funding patterns, where New Investigators (applicants who have never received an R01; Figure 7) have a success rate of 13%, the success rates for R21 funding of new investigators are 10%. This is notably lower than the 19% success rate for experienced investigators (applicants who have received a prior R01 award; Figure 6) for both R01 and R21 (Table 1). This disparity results from the fact that R01 applications, but not R21 applications, from early stage investigators are given preferential consideration. As explained in footnote 3 above, early stage investigators are new investigators within 10 years of receiving their highest degree or completing their clinical training who have not had an R01 award or other substantial NIH independent research award; Figure 8. Although R21 success rates for new investigators are lower than for experienced investigators (10% vs. 19%), new investigators received almost half of all R21 awards (98 vs. 218).
NCI FY2022: R21 Applications, Awards, and Success Rates
Figure 5: All Investigators: Experienced, New and Early Stage
NCI FY2022 Competing R21 Applications and Awards
Figure 7: New Investigators (Includes Early Stage Investigators)
NCI applied the same R01 criteria to identify new and early stage investigators. For Success Rate comparisons, refer to Tables 1 and 2 below.
Figures 5-8: Excludes applications that did not receive a percentile ranking. When an amended application is considered in the same fiscal year as the original, only the one with the better ranking is counted.
Table 1: Fiscal Year 2022: Success Rates (unsolicited R01's, R37's and R21's)
|Total Applications||Number With Percentiles
|Number With Percentiles
|R01/R37 - All Investigators||5,575||1,131||680||805||14%|
|Experienced Investigators - Total||3,989||885||540||601||15%|
|Type 3 / Type 4 Board||9||7||7||8||89%|
|New Investigators - Total1||1,586||246||140||204||13%|
|Early Stage Investigators2||764||142||83||133||17%|
|R21 - All Investigators||1,603||364||223||218||14%|
|Early Stage Investigators2||262||61||34||32||12%|
Includes Cancer MoonshotSM
Total new and competing renewal applications include those that received either a percentile, an impact score, as well as those that were not discussed (triaged) or were not recommended for funding.
Funded R01s include competing revisions. In FY2022, 58 R01s were converted to R37s.
1 Includes Early Stage Investigators
2 Included in New Investigators
Type 1 - New; Type 2 - Competing Renewal; Type 3 - Competing Revision; Type 4 - Extension
The NIH does not report the R21 grants in terms of experienced and new investigators; NCI applied R01 criteria to identify those parameters.
Table 2: All Competing Research Project Grants
|FY 2018||FY 2019||FY 2020||FY 2021||FY 2022|
|Requested||Funded||Success Rate||Requested||Funded||Success Rate||Requested||Funded||Success Rate||Requested||Funded||Success Rate||Requested||Funded||Success Rate|
|R01/R37 - Unsolicited1||5,864||676||12%||5,912||687||12%||6,053||797||13%||5,740||811||14%||5,575||805||14%|
|R21 - Unsolicited||2,100||187||9%||1,861||170||9%||1,563||149||10%||1,770||206||12%||1,603||218||14%|
|R03 - Unsolicited||564||60||11%||505||60||12%||537||61||11%||469||60||13%||382||59||15%|
|Total Competing RPGs:||10,317||1,162||11%||10,108||1,178||12%||9,538||1,217||13%||9,701||1,333||14%||8,932||1,358||15%|
Includes Cancer MoonshotSM
1 Funded R01/R37s include competing revisions. In FY2022 58 R01s were converted to R37s.
2 The Provocative Questions (PQ) RFA did not compete in FY2020 or FY2022, but competed in FY2021.
3 Other RFAs include UM1, R33, P01, U01, U19, UH2, UH3 and UG3.
4 Other RPGs include DP2, P01, R15, R56, U01, U19, UH2, UH3, UM1, UG3, R00, and R61.
Funding Patterns for other years are posted at: Articles.